Neoantigen Targeted Therapies Extract Market 2024 -2033: Global Outlook, Industry Share, Business Growth And Major Players | F. Hoffmann-La Roche AG, Merck and Co. Inc., Bristol Myers Squibb Company, GlaxoSmithKline PLC, Eli Lilly and Company, Kite Pharma

The Business Research Company offers in-depth market insights through Neoantigen Targeted Therapies Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The neoantigen targeted therapies market size has grown exponentially in recent years. It will grow from $2.43 billion in 2023 to $3.39 billion in 2024 at a compound annual growth rate (CAGR) of 39.3%. The growth in the historic period can be attributed to advancements in genomic sequencing, immunotherapy evolution, understanding tumor immunology, clinical success of checkpoint inhibitors, molecular profiling advancements.

The neoantigen targeted therapies market size is expected to see exponential growth in the next few years. It will grow to $11.69 billion in 2028 at a compound annual growth rate (CAGR) of 36.3%. The growth in the forecast period can be attributed to advancements in bioinformatics, precision medicine expansion, neoantigen vaccine development, therapeutic combination strategies, biomarker validation. Major trends in the forecast period include neoantigen resistance management, neoantigen-primed adoptive cell therapies, neoantigen-based combinatorial therapies, integration of real-world data, enhanced predictive models.

Get Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=11944&type=smp

Market Segmentation:
The neoantigen targeted therapies market covered in this report is segmented -
1) By Type: Monotherapy, Combination Therapy
2) By Immunotherapy Type: DNA Or RNA-Based Vaccines, Protein-Based Vaccines, Dendritic Cell Vaccines, TIL-Based Therapies
3) By Target Disease Indication: Colorectal Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Bone Cancer, Gynecological Cancer
4) By Route of Administration: Intradermal, Intravenous, Subcutaneous
5) By Application: Medical Research Institution, Hospital, and Clinic, Other Applications

Major Driver - Rising Incidence Of Cancer Cases Drives Growth In The Neoantigen Targeted Therapies Market
The increasing incidence of cancer cases is expected to propel the growth of the neoantigen targeted therapies market going forward. The incidence of cancer refers to the number of new cases of cancer in a specific population for a given period. Neoantigen targeted therapies are often used in combination to treat different types of cancer. For instance, the American Cancer Society (ACS), a US-based voluntary health organization, in 2022, the United States had 1.9 million new cancer cases, representing a significant increase compared to previous years. Furthermore, in 2022, in the US, approximately 609,360 deaths were attributed to cancer, emphasizing the profound severity and impact of this disease on individuals and their families. Therefore, the increasing incidence of cancer cases is driving the growth of the neoantigen targeted therapies market.

Competitive Landscape:
Major companies operating in the neoantigen targeted therapies market report are F. Hoffmann-La Roche AG, Merck and Co. Inc., Bristol Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, Kite Pharma Inc., Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE, Bavarian Nordic Inc., Advaxis Inc., Immatics NV, Precision Biologics Inc., Iovance Biotherapeutics Inc., Agenus Inc., Achilles Therapeutics Plc, Medigene AG, Gritstone Bio Inc., SQZ Biotechnologies Company, Aduro BioTech Inc., Inovio Pharmaceuticals Inc., Gradalis Inc., EpiVax Inc., ISA Pharmaceuticals BV, Vaxon Biotech SA, Ziopharm Oncology, Genocea Biosciences Inc., Cellular Biomedicine Group Inc., Immunovaccine Inc.

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/neoantigen-targeted-therapies-global-market-report

Top Trend - Biontech Takes Strides In Neoantigen Targeted Therapies With The Launch Of Bnt122 For Colorectal Cancer
Product innovation has emerged as a key trend gaining popularity in the neoantigen targeted therapies market. Major players are focusing on creating innovative products to lead the market. For instance, in October 2021, BioNTech, a Germany-based biotechnology company, expanded its clinical oncology portfolio with the initiation of a Phase 2 clinical trial for 'BNT122', a mRNA-based individualized immunotherapy. This trial specifically focuses on colorectal cancer patients. The trial marks an important milestone, as the first patient has been dosed with BNT122. It is designed to harness the power of the immune system by stimulating a targeted T-cell response against neoantigens found in each patient's tumor. The ongoing clinical trial represents an important step forward in BioNTech's mission to develop cutting-edge immunotherapies and expand the treatment options available to cancer patients.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Neoantigen Targeted Therapies Market Characteristics
3. Neoantigen Targeted Therapies Market Trends And Strategies
4. Neoantigen Targeted Therapies Market - Macro Economic Scenario
5. Neoantigen Targeted Therapies Market Size And Growth
…..
27. Neoantigen Targeted Therapies Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

This release was published on openPR.